PF-07104091 as a Single Agent and in Combination Therapy

Conditions

• Small Cell Lung Cancer
• Ovarian Cancer
• Breast Cancer

Interventions

• DRUG: PF-07104091 monotherapy dose escalation
• DRUG: PF-07104091 + palbociclib + fulvestrant
• DRUG: PF-07104091 + palbociclib + letrozole
• DRUG: PF-07104091 monotherapy dose expansion (ovarian)
• DRUG: PF-07104091 monotherapy dose expansion (SCLC)
• DRUG: PF-07104091 + Fulvestrant (post CDK4/6)
• DRUG: PF-0704091 + Fulvestrant (post CDK4/6)

Sponsor

Pfizer